Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors

Journal of Pathology

Volumn 227, Issue 4, 2012, Pages 404-416

  Chung, Alicia S ^a   Kowanetz, Marcin ^a   Wu, Xiumin ^a   Zhuang, Guanglei ^a   Ngu, Hai ^a   Finkle, David ^a   Komuves, Laszlo ^a   Peale, Franklin ^a   Ferrara, Napoleone ^a  

^a GENENTECH INC   (United States)

Author keywords

anti VEGF; endothelium; metastasis; sunitinib; tumour; VEGF

Indexed keywords

PROTEIN TYROSINE KINASE; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL PERMEABILITY; BREAST TUMOR; CELL CULTURE; CELL JUNCTION; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM; EXTRAVASATION; FEMALE; INTRACELLULAR SIGNALING; LUNG BLOOD VESSEL; LUNG METASTASIS; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; INDOLES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PIPERAZINES; PROTEIN-TYROSINE KINASES; PYRIDINES; PYRIMIDINES; PYRROLES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863718886     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4052     Document Type: Article

References (49)

1. Ferrara N,. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
2. Ebos JM, Kerbel RS,. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011; 8: 210-221.
3. Chung AS, Lee J, Ferrara N,. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 2010; 10: 505-514.
4. Crawford Y, Ferrara N,. VEGF inhibition: insights from preclinical and clinical studies. Cell Tissue Res 2009; 335: 261-269.
5. Padera TP, Kuo AH, Hoshida T, et al., Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. Mol Cancer Ther 2008; 7: 2272-2279.
6. Skobe M, Rockwell P, Goldstein N, et al., Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 1997; 3: 1222-1227.
7. Ebos JM, Lee CR, Cruz-Munoz W, et al., Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-239.
8. Paez-Ribes M, Allen E, Hudock J, et al., Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-231.
9. Sennino B, Ishiguro-Oonuma T, Wei Y, et al., Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov 2012; 2: 270-287.
10. Davis-Smyth T, Chen H, Park J, et al., The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. EMBO J 1996; 15: 4919-4927.
11. Malik AK, Baldwin ME, Peale F, et al., Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. Blood 2006; 107: 550-557.
12. Christensen JG,. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 2007; 18:(suppl 10): x3-10.
13. Wilhelm SM, Adnane L, Newell P, et al., Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7: 3129-3140.
14. Liang WC, Wu X, Peale FV, et al., Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 2006; 281: 951-961.
15. Zetter BR,. Angiogenesis and tumor metastasis. Annu Rev Med 1998; 49: 407-424.
16. Baffert F, Le T, Sennino B, et al., Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling. Am J Physiol Heart Circ Physiol 2006; 290: H547-559.
17. Engelhardt B, Wolburg H,. Mini-review: transendothelial migration of leukocytes: through the front door or around the side of the house? Eur J Immunol 2004; 34: 2955-2963.
18. Karaman MW, Herrgard S, Treiber DK, et al., A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008; 26: 127-132.
19. Olsson AK, Dimberg A, Kreuger J, et al., VEGF receptor signallingâ€"in control of vascular function. Nat Rev Mol Cell Biol 2006; 7: 359-371.
20. 14C sunitinib in rats, monkeys, and humans. Drug Metab Dispos 2012; 40: 539-555.
21. Manning BD,. Balancing Akt with S6K: implications for both metabolic diseases and tumorigenesis. J Cell Biol 2004; 167: 399-403.
22. Ohta T, Eguchi R, Suzuki A, et al., Hypoxia-induced apoptosis and tube breakdown are regulated by p38 MAPK but not by caspase cascade in an in vitro capillary model composed of human endothelial cells. J Cell Physiol 2007; 211: 673-681.
23. Eguchi R, Naitou H, Kunimasa K, et al., Proteomic analysis of hypoxia-induced tube breakdown of an in vitro capillary model composed of HUVECs: potential role of p38-regulated reduction of HSP27. Proteomics 2008; 8: 2897-2906.
24. Liao F, Li Y, O'Connor W, et al., Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Res 2000; 60: 6805-6810.
25. Weis S, Cui J, Barnes L, et al., Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. J Cell Biol 2004; 167: 223-229.
26. Sweeney P, Karashima T, Kim SJ, et al., Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 2002; 8: 2714-2724.
27. Patel D, Bassi R, Hooper AT, et al., Enhanced suppression of melanoma tumor growth and metastasis by combined therapy with anti-VEGF receptor and anti-TYRP-1/gp75 monoclonal antibodies. Anticancer Res 2008; 28: 2679-2686.
28. Maione F, Capano S, Regano D, et al., Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice. J Clin Invest 2012; 122: 1832-1848.
29. Pidgeon GP, Harmey JH, Kay E, et al., The role of endotoxin/ lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer 1999; 81: 1311-1317.
30. Miles D, Harbeck N, Escudier B, et al., Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J Clin Oncol 2011; 29: 83-88.
31. Burger RA, Brady MF, Bookman MA, et al., Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011; 365: 2473-2483.
32. Allegra CJ, Yothers G, O'Connell MJ, et al., Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2011; 29: 11-16.
33. Perren TJ, Swart AM, Pfisterer J, et al., A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011; 365: 2484-2496.
34. Loges S, Mazzone M, Hohensinner P, et al., Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell 2009; 15: 167-170.
35. Xian X, Hakansson J, Stahlberg A, et al., Pericytes limit tumor cell metastasis. J Clin Invest 2006; 116: 642-651.
36. Cooke VG, Lebleu VS, Keskin D, et al., Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by Met signaling pathway. Cancer Cell 2012; 21: 66-81.
37. Singh M, Couto S, Forrest W, et al., Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumor models. J Pathol 2012; 10.1002/path.4053.
38. Ebos JM, Lee CR, Christensen JG, et al., Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007; 104: 17069-17074.
39. Shojaei F, Wu X, Qu X, et al., G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA 2009; 106: 6742-6747.
40. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6: 409-421.
41. + cells in cancer animal models. Int Immunol 2006; 18: 1-9.
42. Grunewald M, Avraham I, Dor Y, et al., VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006; 124: 175-189.
43. Kaplan RN, Riba RD, Zacharoulis S, et al., VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438: 820-827.
44. + granulocytes. Proc Natl Acad Sci USA 2010; 107: 21248-21255.
45. Dejana E, Orsenigo F, Lampugnani MG,. The role of adherens junctions and VE-cadherin in the control of vascular permeability. J Cell Sci 2008; 121: 2115-2122.
46. Gerber HP, Wu X, Yu L, et al., Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci USA 2007; 104: 3478-3483.
47. Bais C, Wu X, Yao J, et al., PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010; 141: 166-177.
48. Ferrara N, Chen H, Davis-Smyth T, et al., Vascular endothelial growth factor is essential for corpus luteum angiogenesis. Nat Med 1998; 4: 336-340.
49. Witte L, Hicklin DJ, Zhu Z, et al., Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metast Rev 1998; 17: 155-161.